Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions

PLoS Neglected Tropical Diseases

Volumn 8, Issue 8, 2014, Pages

  Whitehorn, James ^a,b   Yacoub, Sophie ^b,c   Anders, Katherine L ^b   Macareo, Louis R ^d   Cassetti, M Cristina ^e   Nguyen Van, Vinh Chau ^f   Shi, Pei Yong ^g   Wills, Bridget ^b,h   Simmons, Cameron P ^b,h,i  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^g NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COMORBIDITY; DENGUE; DISEASE SEVERITY; DISEASE TRANSMISSION; FEVER; HUMAN; RISK ASSESSMENT; ANIMAL; CLINICAL TRIAL (TOPIC); MOUSE; RHESUS MONKEY;

ANTIVIRUS AGENT;

ANIMALS; ANTIVIRAL AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DENGUE; HUMANS; MACACA MULATTA; MICE;

EID: 84911911695     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003025     Document Type: Article

References (71)

1. Simmons CP, Farrar JJ, Nguyen vV, Wills B, (2012) Dengue. N Engl J Med 366: 1423–1432.
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504–507.
3. Halstead SB, (1989) Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11 Suppl 4: S830–S839.
4. O'Sullivan MA, Killen HM, (1994) The differentiation state of monocytic cells affects their susceptibility to infection and the effects of infection by dengue virus. J Gen Virol 75(Pt 9): 2387–2392.
5. Nguyet MN, Duong TH, Trung VT, Nguyen TH, Tran CN, et al. (2013) Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 110: 9072–9077.
6. Lam P, Tam D, Diet T, Tam C, Tien N, et al. (2013) Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis 57: 1577–1586.
7. Whitehorn J, Simmons CP, (2011) The pathogenesis of dengue. Vaccine 29: 7221–7228.
8. WHO (2009) Dengue: guidelines for diagnosis, treatment, prevention and control - New edition. Geneva: World Health Organisation.
9. Dimaano EM, Saito M, Honda S, Miranda EA, Alonzo MT, et al. (2007) Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 77: 1135–1138.
10. Jacobs J, Fernandez EA, Merizalde B, Avila-Montes GA, Crothers D, (2007) The use of homeopathic combination remedy for dengue fever symptoms: a pilot RCT in Honduras. Homeopathy 96: 22–26.
11. Kularatne SA, Walathara C, Mahindawansa SI, Wijesinghe S, Pathirage MM, et al. (2009) Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study. Postgrad Med J 85: 525–529.
12. de Castro RA, de Castro JA, Barez MY, Frias MV, Dixit J, et al. (2007) Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration of anti-D (Rh(0)-D) immune globulin. Am J Trop Med Hyg 76: 737–742.
13. Castro JE, Vado-Solis I, Perez-Osorio C, Fredeking TM, (2011) Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue Fever. Clin Dev Immunol 2011: 370872.
14. Salgado D, Zabaleta TE, Hatch S, Vega MR, Rodriguez J, (2012) Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. Pediatr Infect Dis J 31: 771–773.
15. Cabrera-Cortina JI, Sanchez-Valdez E, Cedas-DeLezama D, Ramirez-Gonzalez MD, (2008) Oral calcium administration attenuates thrombocytopenia in patients with dengue fever. Report of a pilot study. Proc West Pharmacol Soc 51: 38–41.
16. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, et al. (2010) A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4: e785.
17. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, et al. (2013) A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 207: 1442–1450.
18. Tam DT, Ngoc TV, Tien NT, Kieu NT, Thuy TT, et al. (2012) Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 55: 1216–1224.
19. Whitehorn J, Van Vinh Chau N, Truong NT, Tai LT, Van Hao N, et al. (2012) Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials 13: 203.
20. Low J, Sung C, Wijaya L, Wei Y, Rathore A, et al. (2014) Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 14: 706–715.
21. Nguyen TH, Nguyen TH, Vu TT, Farrar J, Hoang TL, et al. (2013) Corticosteroids for dengue - why don't they work? PLoS Negl Trop Dis 7: e2592.
22. Chen YL, Ghafar N, Karuna R, Fu Y, Lim SP, et al. (2013) Activation of PBMCs by dengue virus infection depotentiates Balapiravir. J Virol 88: 1740–1747.
23. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM, et al. (2012) Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res 96: 32–35.
24. Durantel D, (2009) Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs 10: 860–870.
25. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, et al. (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816.
26. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI, (2008) Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61: 774–785.
27. Schmidt H, Hennen R, Keller A, Russ M, Muller-Werdan U, et al. (2006) Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 32: 1248–1251.
28. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK, (2012) Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med 27: 280–286.
29. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, et al. (2005) Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 353: 877–889.
30. Dung NM, Day NP, Tam DT, Loan HT, Chau HT, et al. (1999) Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis 29: 787–794.
31. Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, et al. (2001) Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 32: 204–213.
32. Huy NT, Thao NT, Ha TT, Lan NT, Nga PT, et al. (2013) Development of clinical decision rules to predict recurrent shock in dengue. Crit Care 17: R280.
33. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, et al. (2012) Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 367: 124–134.
34. Vincent JL, Kellum JA, Shaw A, Mythen MG, (2013) Should hydroxyethyl starch solutions be totally banned? Crit Care 17: 193.
35. Cavalcanti LP, Vilar D, Souza-Santos R, Teixeira MG, (2011) Change in age pattern of persons with dengue, northeastern Brazil. Emerg Infect Dis 17: 132–134.
36. Ooi EE, Goh KT, Gubler DJ, (2006) Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis 12: 887–893.
37. Whitehorn J, Roche RR, Guzman MG, Martinez E, Gomez WV, et al. (2012) Prophylactic platelets in dengue: survey responses highlight lack of an evidence base. PLoS Negl Trop Dis 6: e1716.
38. Lye DC, Lee VJ, Sun Y, Leo YS, (2009) Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis 48: 1262–1265.
39. Thomas L, Kaidomar S, Kerob-Bauchet B, Moravie V, Brouste Y, et al. (2009) Prospective observational study of low thresholds for platelet transfusion in adult dengue patients. Transfusion 49: 1400–1411.
40. Lum LC, Goh AY, Chan PW, El-Amin AL, Lam SK, (2002) Risk factors for hemorrhage in severe dengue infections. J Pediatr 140: 629–631.
41. Lum LC, Abdel-Latif Mel A, Goh AY, Chan PW, Lam SK, (2003) Preventive transfusion in Dengue shock syndrome-is it necessary? J Pediatr 143: 682–684.
42. Khan Assir MZ, Kamran U, Ahmad HI, Bashir S, Mansoor H, et al. (2013) Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial. Transfus Med Hemother 40: 362–368.
43. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, et al. (2013) Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100: 500–519.
44. Yin Z, Chen YL, Schul W, Wang QY, Gu F, et al. (2009) An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A 106: 20435–20439.
45. Xie X, Wang QY, Xu HY, Qing M, Kramer L, et al. (2011) Inhibition of dengue virus by targeting viral NS4B protein. J Virol 85: 11183–11195.
46. Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, et al. (2013) An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res 98: 35–43.
47. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, et al. (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4: 139ra183.
48. Neyts J, (2006) Selective inhibitors of hepatitis C virus replication. Antiviral Res 71: 363–371.
49. Caly L, Wagstaff KM, Jans DA, (2012) Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? Antiviral Res 95: 202–206.
50. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA, (2012) Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 443: 851–856.
51. Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, et al. (2012) Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 67: 1884–1894.
52. Schul W, Yip A, Shi PY, (2013) Testing antiviral compounds in a dengue mouse model. Methods Mol Biol 1030: 269–281.
53. Zompi S, Harris E, (2012) Animal models of dengue virus infection. Viruses 4: 62–82.
54. Chau TN, Anders KL, Lien le B, Hung NT, Hieu LT, et al. (2010) Clinical and virological features of Dengue in Vietnamese infants. PLoS Negl Trop Dis 4: e657.
55. Halstead SB, Shotwell H, Casals J, (1973) Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128: 7–14.
56. Ajariyakhajorn C, Mammen MP, JrEndy TP, Gettayacamin M, Nisalak A, et al. (2005) Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. Antimicrob Agents Chemother 49: 4508–4514.
57. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, et al. (2010) Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 115: 1823–1834.
58. Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, et al. (2011) Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol 92: 2272–2280.
59. Thomas SJ, (2013) Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother 9: 1587–1590.
60. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, et al. (2013) Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 207: 700–708.
61. Deanfield JE, Halcox JP, Rabelink TJ, (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115: 1285–1295.
62. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, et al. (2008) Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis 198: 602–608.
63. Davis JS, Yeo TW, Thomas JH, McMillan M, Darcy CJ, et al. (2009) Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study. Crit Care 13: R155.
64. De Backer D, Ospina-Tascon G, Salgado D, Favory R, Creteur J, et al. (2010) Monitoring the microcirculation in the critically ill patient: current methods and future approaches. Intensive Care Med 36: 1813–1825.
65. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL, (2002) Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166: 98–104.
66. Ospina-Tascon G, Neves AP, Occhipinti G, Donadello K, Buchele G, et al. (2010) Effects of fluids on microvascular perfusion in patients with severe sepsis. Intensive Care Med 36: 949–955.
67. Buchele GL, Silva E, Ospina-Tascon GA, Vincent JL, De Backer D, (2009) Effects of hydrocortisone on microcirculatory alterations in patients with septic shock. Crit Care Med 37: 1341–1347.
68. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, et al. (2007) Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med 204: 2693–2704.
69. Clough G, Cracowski JL, (2012) Spotlight issue: Microcirculation-from a clinical perspective. Microcirculation 19: 1–4.
70. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559–1567.
71. Simmons CP, Wolbers M, Nguyen MN, Whitehorn J, Shi PY, et al. (2012) Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis 6: e1752.